Welcome to our dedicated page for ProPhase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.
ProPhase Labs, Inc. (PRPH) is a diversified natural health medical science company that specializes in providing a wide range of diagnostic and consumer products. The company's operations are divided into two primary segments: Diagnostic Services and Consumer Products.
The Diagnostic Services segment offers COVID-19 diagnostic testing to a broad range of customers across the United States, including health plans, third-party payers, and government organizations. This segment is focused on delivering timely and accurate diagnostic information, critical during the ongoing pandemic and beyond.
The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) healthcare products and dietary supplements within the United States. In addition to these offerings, ProPhase Labs also provides personal genomics products and services, enabling consumers to gain insights into their genetic makeup.
ProPhase Labs is committed to advancing health and wellness through innovative products and services. Recent achievements include the development of the BE-Smart Esophageal Cancer Test, leveraging the company's AI platform and extensive genomics database. This test represents a significant step forward in cancer diagnostics and showcases the company's commitment to leveraging advanced technologies for improved healthcare outcomes.
Moreover, ProPhase Labs has projects such as Project ZenQ-AI and Equivir, which underline the company's focus on continuous research and innovation. These initiatives highlight ProPhase Labs' role in pushing the boundaries of medical science and consumer health products.
Financially, ProPhase Labs maintains a solid position, with ongoing projects and partnerships further strengthening its market presence. The company actively communicates with its retail investors through multiple channels, ensuring transparency and engagement with its stakeholders.
For more information, visit ProPhase Labs.
ProPhase Labs, Inc. (Nasdaq: PRPH) announced the grant of a stock option to a new employee, consisting of 100,000 shares of common stock. This inducement award was made under Nasdaq Rule 5635(c)(4), not within the company's equity plan. The exercise price is set at $5.76 per share, equal to the stock’s closing price on November 19, 2021. Vesting occurs over four years, starting with 25% on the grant date, and the option has a term of seven years. ProPhase, a diversified biotech firm, focuses on genomics and diagnostic services, including COVID-19 testing.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a strong financial performance for Q3 2021, achieving $9.5 million in total revenue, a 150% increase from $3.8 million in Q3 2020. The company performed 57,000 diagnostics tests in the quarter but reported a net loss of $4.0 million or $(0.26) per share. Cash and equivalents stood at $22.9 million with net working capital of $34.0 million. ProPhase acquired Nebula Genomics for $14.6 million and is optimistic about increasing testing volumes and expanding its diagnostics business.
ProPhase Labs (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present at the virtual Q4 Investor Summit Conference on November 16, 2021, at 2:00 PM ET. The conference runs from November 16-17, 2021, and investors can register online. Karkus will also be available for one-on-one meetings during the event.
ProPhase Labs focuses on genomics testing, COVID-19 testing, and consumer healthcare products. The company aims to leverage its CLIA lab services for whole genome sequencing and has a broad range of diagnostic services.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on November 12, 2021, at 11:00 a.m. ET to discuss Q3 results ending September 30, 2021. CEO Ted Karkus will lead the call, followed by a Q&A session. Registration is necessary to access the call, with a toll-free dial-in option available. ProPhase is a diversified biotech firm focused on genomic testing and CLIA lab services, including COVID-19 testing. The company aims to build a genomic database and expand its services internationally.
ProPhase Labs (NASDAQ: PRPH) announced a decline in expected Q3 2021 COVID-19 testing revenues due to lower summer testing rates. However, the company anticipates a rebound in Q4 2021, aiming to match record Q1 revenues driven by government mandates and an increasing customer base. CEO Ted Karkus noted heightened testing levels in October and ongoing organic growth. The integration of Nebula Genomics into ProPhase's operations is advancing as planned, promising faster genomic testing and lower prices, which may significantly boost sales in 2022.
GARDEN CITY, NY, Oct. 6, 2021 -- ProPhase Labs, Inc. (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present virtually at the 14th Annual LD Micro Main Event Conference. This presentation is scheduled for October 14, 2021, at 9:30 AM ET. ProPhase Labs is a diversified biotech and genomics company, leveraging its CLIA lab services for whole genome sequencing and COVID-19 testing. The company aims to expand its testing capabilities globally and enhance its genomics database for research purposes.
ProPhase Labs, Inc. (Nasdaq: PRPH) announced that CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, virtually held from September 29-30, 2021. Karkus's presentation is scheduled for September 29 at 2:20 PM ET. Investors can register for the conference online. ProPhase Labs is a diversified biotech and genomics company focused on whole genome sequencing and CLIA lab services, including COVID-19 testing. The firm also aims to expand its testing services internationally and enhance genomic data research.
ProPhase Labs (NASDAQ: PRPH) has authorized a stock repurchase program of up to $6 million to enhance shareholder value. The buyback will occur over the next six months via various market transactions, with decisions based on market conditions and company needs. CEO Ted Karkus expressed confidence in the company's momentum, anticipating strong revenue growth for ProPhase Diagnostics due to ongoing COVID-19 testing demand. Additionally, the integration of Nebula Genomics is expected to boost personalized medicine initiatives, aiming for reduced costs and faster results.
ProPhase Labs, a diversified biotech and genomics company, announced that its Chairman and CEO, Ted Karkus, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. Karkus's corporate presentation will be available starting September 13 at 7:00 AM ET. Investors can register for the event on the conference website. ProPhase Labs focuses on genomics testing technologies and offers various diagnostic services, including COVID-19 testing, with results provided in under 24 hours.
ProPhase Labs (Nasdaq: PRPH) has announced that Chairman and CEO Ted Karkus will present at two upcoming investor conferences. He is set to deliver a corporate presentation at the Q3 Investor Summit on August 17, 2021, at 11:00 am ET. Additionally, he will present at the SNN Network Summer Virtual Event on August 18, 2021, at 2:00 pm ET. Management will be available for one-on-one meetings throughout both events. ProPhase Labs focuses on genomics testing and provides COVID-19 testing services.
FAQ
What is the current stock price of ProPhase Labs (PRPH)?
What is the market cap of ProPhase Labs (PRPH)?
What does ProPhase Labs, Inc. do?
What are the main segments of ProPhase Labs' operations?
What services does the Diagnostic Services segment provide?
What products are offered in the Consumer Products segment?
What is the BE-Smart Esophageal Cancer Test?
What recent projects has ProPhase Labs undertaken?
How does ProPhase Labs engage with its investors?
How does ProPhase Labs contribute to healthcare?
